TARGET AUDIENCE
This activity is intended for medical oncologists, urologists and radiation oncologists.

OVERVIEW OF ACTIVITY
Cancers of the genitourinary (GU) system affect hundreds of thousands of individuals within the United States each year and account for almost 30% of new cancer diagnoses. Although GU cancers are a diverse array of distinct diseases, tumors of the bladder, kidney (and renal pelvis) and prostate are among the most prevalent and are therefore the topic of extensive ongoing research. As such, the clinical management of these diseases is currently in a state of evolution, necessitating rapid and consistent access to learning opportunities for clinicians who provide care for these patients. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, urologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with GU cancers.

LEARNING OBJECTIVES
• Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with castration-resistant prostate cancer (PC), and use this information to guide therapeutic decision-making.
• Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.
• Develop an evidence-based approach to the sequencing of systemic therapies for patients with advanced renal cell carcinoma (RCC), incorporating tyrosine kinase inhibitors, anti-VEGF antibodies and mTOR inhibitors.
• Recognize toxicities attributable to diverse molecular-targeted treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.
• Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies in patients with metastatic RCC and bladder cancer.
• Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of the Yale School of Medicine and Research To Practice. The Yale School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Yale School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GUPerspectives16/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
It is the policy of Research To Practice and Yale Continuing Medical Education to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Yale Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Charles G Drake, MD, PhD
Co-Director, Multi-D Prostate Cancer Clinic  
Co-Director, Division of Immunology  
Professor of Oncology, Urology and Immunology  
Johns Hopkins Sidney Kimmel Cancer Center  
Baltimore, Maryland


Daniel J George, MD
Professor of Medicine and Surgery  
Director of Genitourinary Oncology Program  
Duke Cancer Institute  
Durham, North Carolina


Leonard G Gomella, MD
The Bernard W Godwin Professor of Prostate Cancer  
Chairman, Department of Urology  
Associate Director, Jefferson Sidney Kimmel Cancer Center  
Clinical Director, Jefferson Sidney Kimmel Cancer Center Network  
Editor-in-Chief, Canadian Journal of Urology  
Philadelphia, Pennsylvania

Advisory Committee: Abbott Laboratories, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Merck; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Merck; Contracted Research: Astellas Pharma Global Development Inc.

Daniel P Petrylak, MD (Co-Chair)
Professor of Medicine  
Director, Prostate and GU Medical Oncology  
Co-Director, Signal Transduction Program  
Yale Cancer Center  
New Haven, Connecticut


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Genentech BioOncology, Janssen Biotech Inc, Merck and Novartis Pharmaceuticals Corporation.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: April 2016
Expiration date: April 2017
A Phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma. NCT02420821


Fizazi K et al. Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts). Genitourinary Cancers Symposium 2015;Abstract 169.


Hoffman-Censits JH et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). Genitourinary Cancers Symposium 2016;Abstract 355.


Motzer R et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). Proc ASCO 2015;Abstract 4506.


Rosenberg J et al. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). Proc ECCO 2015;Abstract 21LBA.